This investigation is designed to examine the intravascular kinetic behavior of apoprotein associated with the very-low-density lipoproteins (VLDL) in man. The incorporation of intravenously injected selenomethionine Se-75 into plasma proteins was examined in ten subjects. A component of the apoprotein associated with the VLDL was isolated by solvent extraction, and was found to have a uniquely short intravascular half-life of one hour, resulting in a plasma flux of 281 mg./day with only 15.3 mg. circulating in the plasma. In patients with abnormal lipemia, this protein was found to have a prolonged intravascular half-life, and an increased intravascular flux of 979 mg./day. This threefold rise in flux was accompanied by an anticipated increased plasma concentration of the isolated protein to levels ranging from 25 to 750 μg./ml., representing a marked rise from the normal plasma concentrations of 4.8 ± 2.9 μg./ml. The data are interpreted as demonstrating a distinct abnormality in the kinetic behavior of Se-75-labeled protein isolated from VLDL from patients with endogenous lipemia.
Skip Nav Destination
Article navigation
Original Contributions|
June 01 1972
Incorporation of SE75 Selenomethionine into a Protein Component of Plasma Very-Low-Density Lipoprotein in Man
R Philip Eaton, M.D.;
R Philip Eaton, M.D.
Departments of Medicine, University of New Mexico School of Medicine
Albuquerque, New Mexico 87106
Washington University School of Medicine
St. Louis, Missouri
Search for other works by this author on:
David M Kipnis, M.D.
David M Kipnis, M.D.
Departments of Medicine, University of New Mexico School of Medicine
Albuquerque, New Mexico 87106
Washington University School of Medicine
St. Louis, Missouri
Search for other works by this author on:
Citation
R Philip Eaton, David M Kipnis; Incorporation of SE75 Selenomethionine into a Protein Component of Plasma Very-Low-Density Lipoprotein in Man. Diabetes 1 June 1972; 21 (6): 744–753. https://doi.org/10.2337/diab.21.6.744
Download citation file: